Published : 18 Sep 2020
Aagami has been appointed by a Portugal headquartered Pharmaceutical Company dedicated to helping Pharmaceutical Customers bring new and off-patent drugs to market.
As per the scope of the assignment, Aagami and its partners shall provide consultation in the form of a report describing the most appropriate regulatory pathway to obtain India marketing authorization for client’s asset, a topical minocycline.
The reporting shall include:
Aagami will be delivering this project along with their Regulatory Expert Associate, which is a 36 years old organization & has provided regulatory consultancy services to various global blue chip as well as emerging pharmaceutical, nutraceutical, cosmeceutical, cosmetic and medical device companies, including Abbott, Adamas, Amgen, Astellas, Boston Scientific, CMIC, Dabur, Eisai, GSK, Guidant, Hisamitsu, Hoya, Johnson & Johnson, Menarini, MSD (Merck), Rohto, Sanofi-Aventis, Santen, Takeda, Teva, UCB, Unilever etc.
With this client win, Aagami is looking forward to cross the 100 clients milestone.